Soligenix Inc (SNGX)
0.3926
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
0.3924
0.00 (0.00%)
After-Hours: 20:00
Soligenix Research and Development Expense (Quarterly): 1.095M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.095M |
| December 31, 2023 | 0.7775M |
| September 30, 2023 | 0.826M |
| June 30, 2023 | 0.7627M |
| March 31, 2023 | 0.9465M |
| December 31, 2022 | 2.358M |
| September 30, 2022 | 1.792M |
| June 30, 2022 | 2.048M |
| March 31, 2022 | 1.747M |
| December 31, 2021 | 2.702M |
| September 30, 2021 | 2.238M |
| June 30, 2021 | 1.937M |
| March 31, 2021 | 1.310M |
| December 31, 2020 | 3.659M |
| September 30, 2020 | 1.266M |
| June 30, 2020 | 2.17M |
| March 31, 2020 | 7.700M |
| December 31, 2019 | 2.359M |
| September 30, 2019 | 2.267M |
| June 30, 2019 | 1.854M |
| March 31, 2019 | 1.643M |
| December 31, 2018 | 2.374M |
| September 30, 2018 | 1.395M |
| June 30, 2018 | 1.170M |
| March 31, 2018 | 1.803M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.900M |
| September 30, 2017 | 0.6057M |
| June 30, 2017 | 1.784M |
| March 31, 2017 | 1.218M |
| December 31, 2016 | 0.8623M |
| September 30, 2016 | 1.177M |
| June 30, 2016 | 0.8278M |
| March 31, 2016 | 1.428M |
| December 31, 2015 | 1.668M |
| September 30, 2015 | 1.259M |
| June 30, 2015 | 1.443M |
| March 31, 2015 | 1.030M |
| December 31, 2014 | 1.754M |
| September 30, 2014 | 1.089M |
| June 30, 2014 | 1.213M |
| March 31, 2014 | 1.031M |
| December 31, 2013 | 0.9575M |
| September 30, 2013 | 1.217M |
| June 30, 2013 | 2.140M |
| March 31, 2013 | 0.7567M |
| December 31, 2012 | 0.8601M |
| September 30, 2012 | 0.3713M |
| June 30, 2012 | 0.501M |
| March 31, 2012 | 0.8768M |
| December 31, 2011 | 1.044M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.7627M
Minimum
Jun 2023
7.700M
Maximum
Mar 2020
2.091M
Average
1.895M
Median
Research and Development Expense (Quarterly) Benchmarks
| Eagle Pharmaceuticals Inc | 9.833M |
| Marinus Pharmaceuticals Inc | 24.12M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 1.535M |